Oral Gonorrhea Treatment Returns With Caveats: Zoliflodacin & Gepotidacin

The landscape of gonorrhea treatment is shifting, with the recent approval of oral therapies offering a potential alternative to traditional injections. However, the path forward isn’t straightforward. While new options like zoliflodacin (Nuzolvence) and gepotidacin (Blujepa) address growing concerns about antibiotic resistance, questions remain about their effectiveness in certain infection sites and the necessitate for robust surveillance to track emerging resistance patterns.

Oral Therapies Arrive Amidst Rising Resistance

For decades, gonorrhea treatment relied on ceftriaxone, typically administered as an injection alongside an oral antibiotic like azithromycin. More recently, guidelines from the U.S. Centers for Disease Control and Prevention (CDC) have streamlined this to a single shot of ceftriaxone. But the rise of Neisseria gonorrhoeae strains resistant to these antibiotics has prompted a search for new solutions. The FDA approved Nuzolvence in December 2025, a granule formulation dissolved in water, and Blujepa shortly after, offering the first new class of antibiotics for bacterial infections in decades. Both are indicated for uncomplicated urogenital gonorrhea in adults and children weighing over a specific threshold (77 pounds for Nuzolvence, 99 pounds for Blujepa).

The approval of these oral medications represents a significant step toward improving patient convenience. Traditional injections can be painful and require a clinic visit, creating barriers to access. As Sarah Martinez, a patient from Austin, Texas, recounted in My Medicine Advisor, the injection process was both physically uncomfortable and disruptive to her function schedule. The availability of pills offers a more discreet and accessible treatment option.

Efficacy and Limitations: Where Do the New Drugs Stand?

Clinical trials have shown promising results. A study of Nuzolvence involving 930 patients demonstrated a bacterial cure rate of 91% within four to eight days, slightly lower than the 96% cure rate observed with standard ceftriaxone treatment, according to the FDA announcement. However, a critical nuance lies in the location of the infection. Current data suggest that the efficacy of zoliflodacin and gepotidacin may be lower in pharyngeal gonorrhea – an infection of the throat – compared to urogenital infections. This is a significant consideration, as pharyngeal gonorrhea is increasingly common, particularly among certain populations.

The FDA approval of Blujepa came with a specific caveat: it’s intended for patients with limited treatment options due to safety concerns or lack of alternatives. This reflects the relatively limited clinical safety data available for gepotidacin compared to other treatments. The agency’s approval was preceded by an earlier approval in March 2025 for urinary tract infections, signaling a broader potential application for this antibiotic.

The Challenge of Surveillance and Resistance

The emergence of antimicrobial resistance is the driving force behind the search for new gonorrhea treatments. N. Gonorrhoeae is remarkably adept at developing resistance mechanisms, and the widespread use of any antibiotic, even new ones, carries the risk of selecting for resistant strains. This is why ongoing surveillance is crucial. The FDA emphasized the “particular importance” of additional treatment options “given the global rise in gonococcal drug resistance,” as stated by Peter Kim, M.D., M.S., director of the CDER Division of Anti-infectives.

However, robust resistance surveillance systems are not universally in place. Effective monitoring requires consistent data collection, standardized testing methods, and rapid communication of findings. Without this infrastructure, it’s difficult to detect emerging resistance patterns early and adjust treatment guidelines accordingly. The World Health Organization (WHO) has identified antimicrobial resistance as a major global health threat and is working to strengthen surveillance efforts worldwide, but significant gaps remain.

What Does This Signify for Patients and Clinicians?

The arrival of oral gonorrhea therapies doesn’t signal the end of ceftriaxone. For many patients with uncomplicated urogenital gonorrhea, ceftriaxone remains a highly effective treatment option. However, the new drugs provide valuable alternatives, particularly for individuals who prefer to avoid injections or who have allergies or other contraindications to ceftriaxone.

Clinicians will need to carefully consider the individual circumstances of each patient when choosing a treatment regimen. Factors to consider include the location of the infection, the patient’s medical history, and local resistance patterns. The CDC and other public health agencies will likely update their treatment guidelines as more data become available on the efficacy and safety of zoliflodacin and gepotidacin.

Looking Ahead: Guidance Updates and Ongoing Research

The introduction of these new therapies is not a static event. Several key processes are underway and will shape the future of gonorrhea treatment. The CDC’s treatment guidelines are regularly reviewed and updated based on the latest scientific evidence. Expect to spot revisions reflecting the availability of oral therapies and any emerging data on their effectiveness and resistance profiles.

Further research is also needed to better understand the long-term impact of these new drugs. Studies are ongoing to evaluate their efficacy in diverse populations and to monitor for the development of resistance. Research is needed to develop new diagnostic tools that can rapidly detect antibiotic resistance, allowing clinicians to tailor treatment to the specific strain of N. Gonorrhoeae infecting a patient. The FDA’s approval of these drugs marks a milestone, but it’s just one step in an ongoing battle against a constantly evolving pathogen.